This study is for subjects with multiple myeloma who have not responded to their most recent treatment. The study is testing an "investigational" (not yet FDA approved drug) study drug called Teclistamab. The primary purpose of this study is to see how teclistamab in combination with daratumumab (Tec-Dara) compares to either daratumumab, pomalidomide, and dexamethasone (DPd) or daratumumab, bortezomib (VELCADE), and dexamethasone (DVd) for treating participants with multiple myeloma who have not responded to their most recent treatment. The study will last for approximately 6 years, but subjects at MUSC can expect to be in the study for approximately 1 and a half years. The duration of the subject's participation will depend on how you respond to the study treatment.
This study is for patients who have been diagnosed with multiple myeloma. The investigational drug in this study is idecabtagene vicleucel (ide-cel). The purpose of this study is to provide the investigational drug as a possible cancer treatment that would otherwise be unavailable. Patients can expect to have about 8 clinic visits and to be in this study for up to 3 months after receiving the study drug and in follow up for up to 15 years.
This study is for patients that have been diagnosed with multiple myeloma. The usual approach for patients with newly diagnosed multiple myeloma who are not in a study, is lenalidomide and dexamethasone in combination with bortezomib or daratumumab. This approach is approved by the Food and Drug Administration (FDA). The purpose of this study is to see if patients who have a small amount of cancer left after initial treatment (called minimal residual disease (MRD)), could benefit from adding a new drug to the usual treatment. The study approach, using a combination of four drugs, is investigational and not approved by the FDA. Patients can expect to be on this study for up to 2 years. Patients will then be followed by their doctor for up to 15 years after completion of the study or until disease progression..
This study is for patients that have been diagnosed with multiple myeloma. The investigational drugs in this study are lenalidomide and daratumumab. The purpose of this study is to compare overall survival between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma patients. Participants can expect to be on this study for up to 7 years. After 7 years, participants may be followed by telephone for up to 15 years from the time they started study treatment.